Literature DB >> 15949850

Immunological patterns identifying disease course and evolution in multiple sclerosis patients.

Roberto Furlan1, Marco Rovaris, Filippo Martinelli Boneschi, Mohsen Khademi, Alessandra Bergami, Maira Gironi, Michela Deleidi, Federica Agosta, Diego Franciotta, Elio Scarpini, Antonio Uccelli, Mauro Zaffaroni, Asli Kurne, Giancarlo Comi, Tomas Olsson, Massimo Filippi, Gianvito Martino.   

Abstract

Reliable, and easy to measure, immunological markers able to denote disease characteristics in multiple sclerosis (MS) patients are still lacking. We applied a multivariate statistical analysis on results obtained by measuring-by real-time RT-PCR-mRNA levels of 25 immunological relevant molecules in PBMCs from 198 MS patients. The combined measurement of mRNA levels of IL-1beta, TNF-alpha, TGF-beta, CCL20 and CCR3 was able to distinguish MS patients from healthy individuals. CXCR5, CCL5, and CCR3 combined mRNA levels identify primary progressive MS patients while TNF-alpha, IL-10, CXCL10 and CCR3 differentiate relapsing MS patients. Our results indicate that multi-parametric analysis of mRNA levels of immunological relevant molecules in PBMCs may represent a successful strategy for the identification of putative peripheral markers of disease state and disease activity in MS patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949850     DOI: 10.1016/j.jneuroim.2005.04.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Lack of clinical manifestation of hereditary haemochromatosis in South African patients with multiple sclerosis.

Authors:  Maritha J Kotze; J Nico P de Villiers; Louise Warnich; Stephen Schmidt; Jonathan Carr; Erna Mansvelt; Elba Fourie; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2006-07-19       Impact factor: 3.584

Review 3.  Definition of non-responders: biological markers.

Authors:  Roberto Furlan
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

4.  Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis.

Authors:  Mehrdad Alirezaei; Howard S Fox; Claudia T Flynn; Craig S Moore; Andrea L O Hebb; Ricardo F Frausto; Virender Bhan; William B Kiosses; J Lindsay Whitton; George S Robertson; Stephen J Crocker
Journal:  Autophagy       Date:  2009-02-05       Impact factor: 16.016

5.  Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.

Authors:  Qin Wang; Sergei Chuikov; Sophina Taitano; Qi Wu; Arjun Rastogi; Samuel J Tuck; Joseph M Corey; Steven K Lundy; Yang Mao-Draayer
Journal:  Int J Mol Sci       Date:  2015-06-17       Impact factor: 5.923

6.  Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.

Authors:  Maria Antonietta Mazzola; Radhika Raheja; Gopal Murugaiyan; Hasan Rajabi; Deepak Kumar; Thomas Pertel; Keren Regev; Russell Griffin; Lilian Aly; Pia Kivisakk; Parham Nejad; Bonny Patel; Nguendab Gwanyalla; Hillary Hei; Bonnie Glanz; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi
Journal:  J Neuroinflammation       Date:  2015-12-30       Impact factor: 8.322

7.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

8.  A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis.

Authors:  Maira Gironi; Marina Saresella; Marco Rovaris; Matilde Vaghi; Raffaello Nemni; Mario Clerici; Enzo Grossi
Journal:  Immun Ageing       Date:  2013-01-10       Impact factor: 6.400

9.  Comparison of Antioxidant Status and Vitamin D Levels between Multiple Sclerosis Patients and Healthy Matched Subjects.

Authors:  Ehsan Hejazi; Reza Amani; Naser SharafodinZadeh; Bahman Cheraghian
Journal:  Mult Scler Int       Date:  2014-04-14

10.  Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.

Authors:  Antonietta Gentile; Alessandra Musella; Silvia Bullitta; Diego Fresegna; Francesca De Vito; Roberta Fantozzi; Eleonora Piras; Francesca Gargano; Giovanna Borsellino; Luca Battistini; Anna Schubart; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroinflammation       Date:  2016-08-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.